Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance …

Mar 17, 2025 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical …

At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together. Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where …

In June 2025, Harrow acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% for the treatment of post-operative inflammation and pain …

Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).

www.harrow.com

Prior to joining Harrow, he was Founder and Chief Executive Officer of LVMA Consulting, advising emerging biotech companies and top 10 global pharmaceutical organizations on commercial …

Sep 15, 2025 · November 24, 2025 Harrow to Present at Two Investor Conferences in December November 18, 2025 Harrow Announces Closing of Acquisition of Melt Pharmaceuticals November …

The content provided by Harrow on this web site and all site-related services is intended to educate and inform you about Harrow, our product candidates and our technology.